Gottlieb: Democratic White House Would Impact FDA Device Policy
This article was originally published in The Gray Sheet
Executive Summary
A switch from Republican to Democratic control of the White House in 2008 could have tangible, near-term policy implications for FDA device and diagnostic oversight and postmarket study requirements, according to a former deputy commissioner with FDA